17 December 2021Mind Medicine Inc. (MNMD.Q) Stays Focused, Initiates Phase 2a LSD…Kieran Robertson MNMD.Q $901.372M Market Capitalization Mind Medicine Inc. (MNMD.Q) today announced the initiation of a Phase 2a proof-of-concept (POC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit…